




The industry leader in latent TB testing

Screen for TB with confidence using
QuantiFERON®-TB Gold Plus



Choosing QFT®-Plus has its advantages:

- The only test that can differentiate CD4 and CD8 T cell responses
- The only test that provides up to 53 hours for sample handling with no reagent additives
- The only FDA-approved automation solution using the LIAISON® QuantiFERON-TB Gold Plus test

The most advanced, most adaptable technology for TB screening

The only technology that can differentiate CD4 and CD8 T cell responses – research studies show:

- CD8 responses are associated with active TB infection (1, 2)
- CD8 responses may indicate recent exposure to TB (3–5)
- CD8 responses are detectable in immunocompromised patients (6–8)

The only solutions that provide up to 53 hours for sample handling with no reagent additives

- Up to two days for sample handling and transport
- Capture additional accounts through geographic expansion
- Consolidate and streamline workflow

The only FDA-approved automation solution using the LIAISON QuantiFERON-TB Gold Plus test

- Fully automated testing with minimal hands-on time
- 46 minutes to first result
- Full patient traceability



Learn more at www.QuantiFERON.com

QuantiFERON-TB Gold Plus Blood Collection Tubes by QIAGEN and LIAISON Analyzer by DiaSorin.

References:

1. Pertuccioli, E. et al. (2016) First characterization of the CD4 and CD8 T-cell responses to QFT-Plus. *J. Infect.* **73**, 588–597.
2. Sotgui, G. et al. (2019) QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. *J. Infect.* **79**, 444–453.
3. Pieterman, E.D. et al. (2018) A multicentre verification study of the QuantiFERON®-TB Gold Plus assay. *Tuberculosis* **108**, 136–142.
4. Pourakbari, B. et al. (2019) Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon- γ release assays: A systematic review and meta-analysis. *Adv. Med. Sci.* **64**, 437–443.
5. Barcellini, L. et al. (2016) First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. *Eur. Resp. J.* **48**, 1411–1419.
6. Barcellini, L. et al. (2016) First independent evaluation of QuantiFERON-TB Plus performance. *Eur. Resp. J.* **47**, 1598–1590.
7. Telesinghe, L. et al. (2017) The sensitivity of the QuantiFERON-TB Gold Plus assay in Zambian adults with active tuberculosis. *Int. J. Tuberc. Lung Dis.* **21**, 690–696.
8. Petruccioli, E. et al. (2020) Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. *J. Infect.* **80**, 536–546.

QFT-Plus is an in vitro diagnostic aid for detection of *Mycobacterium tuberculosis* infection. QFT-Plus is an indirect test for *M. tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts as well as up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

Trademarks: QIAGEN®, Sample to Insight®, QuantiFERON®, QFT® (QIAGEN Group); LIAISON® (DiaSorin). Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

PROM-16631-001 1122310 08/2020 © 2020 QIAGEN, all rights reserved.